Respiratory failure & ventilation
Extracorporeal Carbon Dioxide Removal With the Hemolung in Patients With Acute Respiratory Failure: A Multicenter Retrospective Cohort Study*
Main finding · Survival to ICU dischargeResult — go to the resultOR for survival to ICU discharge 6.57 95% CI 2.03–21.33Authors' conclusion
Significant improvement in hypercapnic acidosis along with reduction in ventilation supports was noted within 4 hours of initiating ECCO 2 R. Non-COVID-19 ARDS, age, and P/F at commencement of ECCO 2 R were independently associated with survival.
Study context
- Population
- Patients with acute respiratory failure treated with the Hemolung, Hemolung Registry (57 ICUs), April 2013–June 2021
- Participants
- 159 patients · 57 ICUs
- Exposure
- ICU survivors vs non-survivors treated with the Hemolung ECCO2R device
- Survivedn = 65
- Outcome
- Survival to ICU discharge
Methodological detailsmulticentre, multinational, registry
- Multicentre
- Multinational
- Registry
Main finding
As reported in the abstract
OR for survival to ICU discharge
6.57
95% CI 2.03–21.33
P/F 100-200 vs P/F <100
OR for survival to ICU discharge 6.57 (95% CI 2.03–21.33)
- Survived to ICU discharge, all patients
- 65 (41%)
- Survival, status asthmaticus
- 86%
- Survival, acute respiratory distress syndrome (ARDS)
- 52%
- Survival, COVID-19 ARDS
- 31%
Observational data: associations, not effects.
Further findings
Survival to ICU discharge by diagnosis (subgroup)
- Status asthmaticus
- 86%
- ARDS
- 52%
- COVID-19 ARDS
- 31%
PaCO2, pH and ventilation support
- Significant reduction in PaCO2 and improvement in pH with reduced mechanical ventilation support in all patients
Characteristics of non-survivors
- Patients who died were older, had lower P/F and higher use of adjunctive therapies
Safety
Complications
- No difference between survivors and non-survivors
Original publication
Extracorporeal Carbon Dioxide Removal With the Hemolung in Patients With Acute Respiratory Failure: A Multicenter Retrospective Cohort Study*. Crit Care Med. Published 21 March 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →